0001171843-23-001261.txt : 20230228 0001171843-23-001261.hdr.sgml : 20230228 20230228163048 ACCESSION NUMBER: 0001171843-23-001261 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeyondSpring Inc. CENTRAL INDEX KEY: 0001677940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38024 FILM NUMBER: 23686008 BUSINESS ADDRESS: STREET 1: 28 LIBERTY STREET STREET 2: 39TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: 646-528-4184 MAIL ADDRESS: STREET 1: 28 LIBERTY STREET STREET 2: 39TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 6-K 1 bysi20230223_6k.htm FORM 6-K bysi20230223_6k.htm
0001677940 BeyondSpring Inc. false --12-31 Q2 2022 June 30, 2022 0.0001 0.0001 500,000,000 500,000,000 38,927,563 38,927,563 38,955,376 38,955,376 00016779402022-01-012022-06-30 iso4217:USD 00016779402021-12-31 00016779402022-06-30 iso4217:USDxbrli:shares xbrli:shares 00016779402021-01-012021-06-30
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2023

 

Commission File Number: 001-38024

 

BeyondSpring Inc.

 

BeyondSpring Inc.
28 Liberty Street, 39th Floor
New York, New York 10005
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

On February 28, 2023, BeyondSpring Inc. (the “Company”) reported financial results for the six months ended June 30, 2022.

 

This Report on Form 6-K is incorporated by reference into the Registration Statements on Form F-3, File No. 333-257639 and File No. 333-249816, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

 

 

 

 

 

BEYONDSPRING INC.

 

AUDITED CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2021 AND

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2022

 

(Amounts in thousands of U.S. Dollars ($), except for number of shares and per share data)

 

  

December 31, 2021

  

June 30, 2022

 
    $    $ 
         

Assets

        

Current assets:

        

Cash and cash equivalents

  41,625   30,740 

Short-term investments

  30,743   21,197 

Advances to suppliers

  1,735   2,164 

Prepaid expenses and other current assets

  1,020   1,628 

Total current assets

  75,123   55,729 
         

Noncurrent assets:

        

Property and equipment, net

  1,422   1,909 

Operating lease right-of-use assets

  1,984   6,013 

Other noncurrent assets

  3,119   114 

Total noncurrent assets

  6,525   8,036 
         

Total assets

  81,648   63,765 
         

Liabilities and equity

        
         

Current liabilities:

        

Accounts payable

  1,656   1,161 

Accrued expenses

  3,858   2,702 

Current portion of operating lease liabilities

  538   811 

Deferred revenue

  1,369   1,351 

Long-term loans, current portion

  1,569   - 

Other current liabilities

  6,165   5,084 

Total current liabilities

  15,155   11,109 
         

Noncurrent liabilities:

        

Operating lease liabilities

  1,468   4,471 

Deferred revenue

  37,939   35,758 

Other noncurrent liabilities

  709   692 

Total noncurrent liabilities

  40,116   40,921 
         

Total liabilities

  55,271   52,030 
         

Commitments and contingencies

          
         

Mezzanine equity

        

Contingently redeemable noncontrolling interests

  5,454   10,674 
         

Equity

        

Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,927,563 and 38,955,376 shares issued and outstanding as of December 31, 2021 and June 30, 2022, respectively)

  4   4 

Additional paid-in capital

  369,200   368,473 

Accumulated deficit

  (341,997)  (360,486)

Accumulated other comprehensive (loss) income

  (523)  117 
         

Total BeyondSpring Inc.’s shareholders’ equity

  26,684   8,108 

Noncontrolling interests

  (5,761)  (7,047)

Total equity

  20,923   1,061 
         

Total liabilities, mezzanine equity and equity

  81,648   63,765 

 

 

 

 

 

BEYONDSPRING INC.

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF

 

COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2022

 

(Amounts in thousands of U.S. Dollars ($), except for number of shares and per share data)

 

   

Six months ended June 30,

 
   

2021

   

2022

 
       $        $  
                 

Revenue

    676       676  
                 

Operating expenses

               

Research and development

    (22,643 )     (13,992 )

General and administrative

    (15,432 )     (7,492 )
                 

Loss from operations

    (37,399 )     (20,808 )

Foreign exchange, net

    44       (350 )

Interest income

    61       41  

Interest expenses

    (46 )     (17 )

Other income, net

    3       1,259  
                 

Loss before income tax

    (37,337 )     (19,875 )

Income tax expenses

    -       (289 )
                 

Net loss

    (37,337 )     (20,164 )

Less: Net loss attributable to noncontrolling interests

    (1,041 )     (1,675 )

Net loss attributable to BeyondSpring Inc.

    (36,296 )     (18,489 )
                 

Net loss per share

               

Basic and diluted

    (0.93 )     (0.47 )
                 

Weighted-average shares outstanding

               

Basic and diluted

    39,007,749       39,065,710  
                 

Other comprehensive loss, net of tax of nil:

               

Foreign currency translation adjustment (loss) gain

    (75 )     949  

Unrealized holding gain

    -       30  

Comprehensive loss

    (37,412 )     (19,185 )

Less: Comprehensive loss attributable to noncontrolling interests

    (1,047 )     (1,336 )

Comprehensive loss attributable to BeyondSpring Inc.

    (36,365 )     (17,849 )

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

BeyondSpring Inc.

   
   
 

By: 

/s/ Lan Huang

 

Name: Lan Huang

 

Title: Chairperson and Chief Executive Officer

 

 

Date: February 28, 2023

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit No.

Exhibit

   

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 
EX-101.SCH 2 bysi-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022 link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 3 bysi-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 4 bysi-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bysi-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Notes To Financial Statements Notes To Financial Statements [Abstract] Note To Financial Statement Details Textual us-gaap_IncomeTaxExpenseBenefit Income tax expenses Noncurrent liabilities: Equity Components [Axis] Equity Component [Domain] Unrealized holding gain Other noncurrent assets us-gaap_LiabilitiesCurrent Total current liabilities Other current liabilities us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income tax Operating expenses Foreign currency translation adjustment (loss) gain Cash and cash equivalents Long-term loans, current portion us-gaap_AssetsCurrent Total current assets Noncurrent assets: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total equity Advances to suppliers Amendment Flag Other comprehensive loss, net of tax of nil: Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss attributable to BeyondSpring Inc. Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,927,563 and 38,955,376 shares issued and outstanding as of December 31, 2021 and June 30, 2022, respectively) Ordinary shares, authorized (in shares) Ordinary shares, outstanding (in shares) Ordinary shares, issued (in shares) Deferred revenue Ordinary shares, par value (in dollars per share) Current Fiscal Year End Date Accrued expenses Document Fiscal Period Focus Document Fiscal Year Focus Accounts payable Document Period End Date Entity File Number Document Type us-gaap_PolicyTextBlockAbstract Accounting Policies Document Information [Line Items] Document Information [Table] Revenue Foreign exchange, net Basic and diluted (in shares) Entity Central Index Key Entity Registrant Name Current liabilities: Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] us-gaap_Assets Total assets Entity Address, City or Town Entity Address, Postal Zip Code Noncontrolling interests Basic and diluted (in dollars per share) Entity Address, State or Province Weighted-average shares outstanding Statement [Line Items] Income Statement [Abstract] Additional paid-in capital Short-term investments Equity Other income, net Current assets: us-gaap_NetIncomeLoss Net loss attributable to BeyondSpring Inc. Contingently redeemable noncontrolling interests us-gaap_TableTextBlock Notes Tables Interest income us-gaap_Liabilities Total liabilities Less: Net loss attributable to noncontrolling interests Commitments and contingencies Mezzanine equity us-gaap_OperatingIncomeLoss Loss from operations Prepaid expenses and other current assets us-gaap_SellingGeneralAndAdministrativeExpense General and administrative us-gaap_LiabilitiesNoncurrent Total noncurrent liabilities Other noncurrent liabilities Less: Comprehensive loss attributable to noncontrolling interests Property and equipment, net us-gaap_PropertyPlantAndEquipmentNet us-gaap_LiabilitiesAndStockholdersEquity Total liabilities, mezzanine equity and equity Accumulated deficit us-gaap_ResearchAndDevelopmentExpense Research and development us-gaap_AssetsNoncurrent Total noncurrent assets Accumulated other comprehensive (loss) income us-gaap_InterestExpense Interest expenses Deferred revenue us-gaap_ContractWithCustomerLiabilityNoncurrent us-gaap_StockholdersEquity Total BeyondSpring Inc.’s shareholders’ equity us-gaap_ProfitLoss Net loss us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive loss us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities Class of Stock [Axis] Current portion of operating lease liabilities us-gaap_OperatingLeaseRightOfUseAsset Operating lease right-of-use assets Net loss per share EX-101.PRE 6 bysi-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
6 Months Ended
Jun. 30, 2022
Document Information [Line Items]  
Entity Central Index Key 0001677940
Entity Registrant Name BeyondSpring Inc.
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2022
Document Type 6-K
Document Period End Date Jun. 30, 2022
Entity File Number 001-38024
Entity Address, Address Line One 28 Liberty Street, 39th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10005
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 30,740 $ 41,625
Short-term investments 21,197 30,743
Advances to suppliers 2,164 1,735
Prepaid expenses and other current assets 1,628 1,020
Total current assets 55,729 75,123
Noncurrent assets:    
Property and equipment, net 1,909 1,422
Operating lease right-of-use assets 6,013 1,984
Other noncurrent assets 114 3,119
Total noncurrent assets 8,036 6,525
Total assets 63,765 81,648
Current liabilities:    
Accounts payable 1,161 1,656
Accrued expenses 2,702 3,858
Current portion of operating lease liabilities 811 538
Deferred revenue 1,351 1,369
Long-term loans, current portion 0 1,569
Other current liabilities 5,084 6,165
Total current liabilities 11,109 15,155
Noncurrent liabilities:    
Operating lease liabilities 4,471 1,468
Deferred revenue 35,758 37,939
Other noncurrent liabilities 692 709
Total noncurrent liabilities 40,921 40,116
Total liabilities 52,030 55,271
Commitments and contingencies
Mezzanine equity    
Contingently redeemable noncontrolling interests 10,674 5,454
Equity    
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,927,563 and 38,955,376 shares issued and outstanding as of December 31, 2021 and June 30, 2022, respectively) 4 4
Additional paid-in capital 368,473 369,200
Accumulated deficit (360,486) (341,997)
Accumulated other comprehensive (loss) income 117 (523)
Total BeyondSpring Inc.’s shareholders’ equity 8,108 26,684
Noncontrolling interests (7,047) (5,761)
Total equity 1,061 20,923
Total liabilities, mezzanine equity and equity $ 63,765 $ 81,648
XML 9 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Ordinary shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Ordinary shares, authorized (in shares) 500,000,000 500,000,000
Ordinary shares, issued (in shares) 38,955,376 38,927,563
Ordinary shares, outstanding (in shares) 38,955,376 38,927,563
XML 10 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022 - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Revenue $ 676 $ 676
Operating expenses    
Research and development (13,992) (22,643)
General and administrative (7,492) (15,432)
Loss from operations (20,808) (37,399)
Foreign exchange, net (350) 44
Interest income 41 61
Interest expenses (17) (46)
Other income, net 1,259 3
Loss before income tax (19,875) (37,337)
Income tax expenses (289) 0
Net loss (20,164) (37,337)
Less: Net loss attributable to noncontrolling interests (1,675) (1,041)
Net loss attributable to BeyondSpring Inc. $ (18,489) $ (36,296)
Net loss per share    
Basic and diluted (in dollars per share) $ (0.47) $ (0.93)
Weighted-average shares outstanding    
Basic and diluted (in shares) 39,065,710 39,007,749
Other comprehensive loss, net of tax of nil:    
Foreign currency translation adjustment (loss) gain $ 949 $ (75)
Unrealized holding gain 30 0
Comprehensive loss (19,185) (37,412)
Less: Comprehensive loss attributable to noncontrolling interests (1,336) (1,047)
Comprehensive loss attributable to BeyondSpring Inc. $ (17,849) $ (36,365)
XML 11 bysi20230223_6k_htm.xml IDEA: XBRL DOCUMENT 0001677940 2022-01-01 2022-06-30 0001677940 2021-12-31 0001677940 2022-06-30 0001677940 2021-01-01 2021-06-30 iso4217:USD iso4217:USD shares shares 0001677940 BeyondSpring Inc. false --12-31 Q2 2022 2022-06-30 0.0001 0.0001 500000000 500000000 38927563 38927563 38955376 38955376 6-K 001-38024 BeyondSpring Inc. 28 Liberty Street, 39th Floor New York NY 10005 41625000 30740000 30743000 21197000 1735000 2164000 1020000 1628000 75123000 55729000 1422000 1909000 1984000 6013000 3119000 114000 6525000 8036000 81648000 63765000 1656000 1161000 3858000 2702000 538000 811000 1369000 1351000 1569000 0 6165000 5084000 15155000 11109000 1468000 4471000 37939000 35758000 709000 692000 40116000 40921000 55271000 52030000 5454000 10674000 4000 4000 369200000 368473000 -341997000 -360486000 -523000 117000 26684000 8108000 -5761000 -7047000 20923000 1061000 81648000 63765000 676000 676000 22643000 13992000 15432000 7492000 -37399000 -20808000 44000 -350000 61000 41000 46000 17000 3000 1259000 -37337000 -19875000 -0 289000 -37337000 -20164000 -1041000 -1675000 -36296000 -18489000 -0.93 -0.47 39007749 39065710 -75000 949000 0 30000 -37412000 -19185000 -1047000 -1336000 -36365000 -17849000 EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 4 69 1 false 0 0 false 3 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 Sheet http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022 Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 Statements 2 false false R3.htm 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals) Sheet http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022 Sheet http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022 Statements 4 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding - bysi20230223_6k.htm 16, 17, 18, 19, 20, 21, 22, 23 bysi20230223_6k.htm bysi-20220630.xsd bysi-20220630_cal.xml bysi-20220630_def.xml bysi-20220630_lab.xml bysi-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bysi20230223_6k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 112, "http://xbrl.sec.gov/dei/2022": 14 }, "contextCount": 4, "dts": { "calculationLink": { "local": [ "bysi-20220630_cal.xml" ] }, "definitionLink": { "local": [ "bysi-20220630_def.xml" ] }, "inline": { "local": [ "bysi20230223_6k.htm" ] }, "labelLink": { "local": [ "bysi-20220630_lab.xml" ] }, "presentationLink": { "local": [ "bysi-20220630_pre.xml" ] }, "schema": { "local": [ "bysi-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 87, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 10, "http://xbrl.sec.gov/dei/2022": 7, "total": 17 }, "keyCustom": 0, "keyStandard": 69, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bysi", "nsuri": "http://www.beyondspringpharma.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "i_2022-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022", "menuCat": "Statements", "order": "2", "role": "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "i_2022-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022", "menuCat": "Statements", "order": "4", "role": "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022", "shortName": "Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bysi20230223_6k.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022", "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals", "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "domainItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022", "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals", "http://www.beyondspringpharma.com/20220630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r21", "r22", "r80", "r190", "r199", "r200" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r209" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances to suppliers" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r53", "r63", "r79", "r96", "r124", "r127", "r131", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r162", "r166", "r171", "r207", "r214", "r215", "r217" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r75", "r81", "r96", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r162", "r166", "r171", "r207", "r214", "r215", "r217" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r96", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r162", "r166", "r171", "r214", "r215", "r217" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total noncurrent assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r30", "r77", "r201" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r58", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Ordinary shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Ordinary shares, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Ordinary shares, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r39" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Ordinary shares, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,927,563 and 38,955,376 shares issued and outstanding as of December 31, 2021 and June 30, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r23", "r85", "r87", "r93", "r186", "r193" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss attributable to BeyondSpring Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss, net of tax of nil:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r45", "r46", "r50", "r85", "r87", "r92", "r185", "r192" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Less: Comprehensive loss attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r44", "r50", "r85", "r87", "r91", "r184", "r191" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r148", "r149", "r152" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r148", "r149", "r152" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "us-gaap_ContractWithCustomerLiabilityNoncurrent", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r94", "r103", "r104", "r105", "r106", "r107", "r111", "r112", "r114", "r115", "r116", "r117", "r169", "r170", "r187", "r194", "r202" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average shares outstanding" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r172", "r173", "r174", "r175" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign exchange, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r24", "r52", "r59", "r70", "r124", "r126", "r130", "r132", "r188", "r204" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r109", "r110", "r123", "r156", "r159", "r160", "r195" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expenses" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r51", "r61", "r90", "r122", "r179" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expenses" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r27", "r121" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r96", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r163", "r166", "r167", "r171", "r203", "r214", "r217", "r218" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r55", "r66", "r207", "r212", "r213", "r216" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities, mezzanine equity and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r76", "r96", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r163", "r166", "r167", "r171", "r207", "r214", "r217", "r218" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r96", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r163", "r166", "r167", "r171", "r214", "r217", "r218" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term loans, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r18", "r54", "r65", "r96", "r136", "r138", "r140", "r141", "r142", "r145", "r146", "r171" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r25", "r29", "r60", "r69", "r74", "r84", "r86", "r89", "r96", "r101", "r103", "r104", "r105", "r106", "r109", "r110", "r113", "r124", "r126", "r130", "r132", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r170", "r171", "r204", "r214" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "us-gaap_NetIncomeLoss", "totalLabel": "Net loss attributable to BeyondSpring Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r47", "r49", "r84", "r86", "r109", "r110", "r211" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: Net loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r124", "r126", "r130", "r132", "r204" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r181" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r181" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r180" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "us-gaap_OperatingLeaseRightOfUseAsset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r78" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r19" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment (loss) gain" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r82", "r83" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized holding gain" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r14", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r210" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r74", "r84", "r86", "r95", "r96", "r101", "r109", "r110", "r124", "r126", "r130", "r132", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r161", "r164", "r165", "r170", "r171", "r188", "r204", "r205", "r206", "r211", "r214" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "us-gaap_ProfitLoss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r34", "r67", "r189", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentNet", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r35", "r36", "r37", "r38" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Contingently redeemable noncontrolling interests" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r41", "r71", "r219" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "us-gaap_ResearchAndDevelopmentExpense", "negatedLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r40", "r64", "r198", "r200", "r207" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r119", "r120", "r125", "r128", "r129", "r133", "r134", "r135", "r150", "r151", "r183" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "us-gaap_SellingGeneralAndAdministrativeExpense", "negatedLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r56", "r57", "r62", "r209" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022", "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals", "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r98", "r99", "r100", "r118", "r183" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022", "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022-parentheticals", "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r33", "r207", "r212", "r213", "r216" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "totalLabel": "Total BeyondSpring Inc.\u2019s shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r42", "r43", "r48", "r72", "r73", "r88", "r98", "r99", "r100", "r102", "r108", "r137", "r147", "r153", "r154", "r155", "r157", "r158", "r168", "r176", "r177", "r178", "r182", "r196", "r197", "r212", "r213", "r216" ], "calculation": { "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mezzanine equity" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2021-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2022" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.beyondspringpharma.com/20220630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2021-and-2022" ], "xbrltype": "sharesItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r208": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 19 0001171843-23-001261-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-001261-xbrl.zip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end